Embed Size (px)
Citation preview
www.MarketResearchReports.com
Graft vs. Host Disease -
Competitive Landscape,
Technology and Pipeline Analysis,
2016
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com
Introduction to Report
Launch Date: July 19, 2016
Number of Pages: 232
Geography Coverage: Global
Available Format: PDF
Price For Single User License: USD 2,450
Price For Site User License: USD 4,900
Price For Global User License: USD 7,350
Delivery Time: Within 24 Hours (During Working Days)
www.MarketResearchReports.com
About the Report
Graft vs. Host Disease- Competitive Landscape, Technology and Pipeline Analysis, 2016 report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Graft Versus Host Disease.
Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host's cells as foreign.
www.MarketResearchReports.com
Key Highlights The complexity of immune-mediated disease occurs
due to the interaction between the adaptive immunity of donor and recipient. It can progress from mild to severe forms as either acute GVHD (aGVHD) or chronic GVHD (cGVHD).
Both aGVHD and cGVHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. It is the worldwide cause of mortality and morbidity.
Several factors are responsible for Graft versus Host Disease such as blood transfusion, bone marrow transplant, stem cell transplant.
This report provides information on the therapeutic development based on the Graft versus Host Disease dealing with around 57 active pipeline drugs.
www.MarketResearchReports.com
Report Highlights:
The new report, provides a Graft Versus Host Disease Landscape across the globe
The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
Coverage of the Graft Versus Host Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for Graft Versus Host Disease and also provide company profiling
www.MarketResearchReports.com
Report Coverage:
1. Executive Summary
2. Overview
3. Pipeline Analysis
4. Market Drivers
5. Pipeline Therapeutics
6. Comparative AnalysisAppendix
www.MarketResearchReports.com
Company Coverage:
1. Bellicum Pharmaceuticals2. Kymab Limited3. Targazyme4. Multistem5. ImmuneTarget Inc.6. Athersys7. AstraZeneca plc.8. Fate Therapeutics, Inc.9. Therakos Inc.10. Mallinckrodt Pharmaceuticals11. Athersys12. AstraZeneca plc.
www.MarketResearchReports.com
Custom Research: Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.
For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center
For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter
www.MarketResearchReports.com
How To Buy This Report?Visit following URL to see Table of Content and purchase this publication:
http://mrr.cm/JRz
About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.
Contact : Sudeep ChakravartyEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)
